ACE 86225106
Alternative Names: ACE-86225106Latest Information Update: 15 Jun 2024
At a glance
- Originator Acerand Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Poly(ADP-ribose) polymerase-1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 22 Mar 2024 Phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease) in China (PO) (NCT06380660)
- 03 Nov 2023 Preclinical trials in Solid tumours in China (PO) before November 2023